Literature DB >> 18550029

MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.

Ki Lui1, Takaya Tamura, Taisuke Mori, Dujin Zhou, Shiuan Chen.   

Abstract

We have previously generated a breast cancer cell line, MCF-7aro, which over-expresses aromatase and is also ER positive. Recently, this MCF-7aro cell line was stably transfected with a promoter reporter plasmid, pGL3-Luc, containing three repeats of estrogen responsive element (ERE). Experiments using MCF-7aro/ERE have demonstrated that it is a novel, non-radioactive screening system for aromatase inhibitors (AIs), ERalpha ligands and ERRalpha ligands. The screening is carried out in a 96-well plate format. To evaluate this system, the cells were cultured overnight in charcoal-dextran stripped FBS medium supplemented with 0.1 nM testosterone or 17beta-estradiol, and various concentrations of antiestrogens or AIs. We found that the luciferase activity was induced when the cells were cultured either in the presence of testosterone or 17beta-estradiol. Furthermore, a 50% decrease in luciferase activity could be achieved when the cells were cultured in the presence of testosterone together with letrozole, anastrozole, tamoxifen or fulvestrant (concentrations being 75 nM, 290 nM, 100 nM, and 5 nM, respectively), compared to the testosterone-only cultured cells. Using this assay system, we confirmed that 3(2'-chlorophenyl)-7-methoxy-4-phenylcoumarin is an agonist of ER. Furthermore, genestein has been shown to be a ligand of ERRalpha because its binding could be blocked by an ERRalpha inverse agonist, XCT790. These results indicate that MCF-7aro/ERE is a novel cell line for rapid screening of AIs, ERalpha ligands and ERRalpha ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18550029      PMCID: PMC2587126          DOI: 10.1016/j.bcp.2008.04.011

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  19 in total

1.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.

Authors:  S Dauvois; P S Danielian; R White; M G Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.

Authors:  G G Kuiper; B Carlsson; K Grandien; E Enmark; J Häggblad; S Nilsson; J A Gustafsson
Journal:  Endocrinology       Date:  1997-03       Impact factor: 4.736

Review 3.  Aromatase activity in the breast and other peripheral tissues and its therapeutic regulation.

Authors:  D W Killinger; E Perel; D Daniilescu; L Kharlip; M E Blackstein
Journal:  Steroids       Date:  1987 Oct-Dec       Impact factor: 2.668

4.  Intratumoral aromatase as a prognostic factor in human breast carcinoma.

Authors:  M C Silva; M G Rowlands; M Dowsett; B Gusterson; J A McKinna; I Fryatt; R C Coombes
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

5.  Purification and characterization of aromatase from human placenta.

Authors:  P F Hall; S Chen; S Nakajin; M Shinoda; J E Shively
Journal:  Steroids       Date:  1987 Jul-Sep       Impact factor: 2.668

6.  Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening.

Authors:  D J Zhou; D Pompon; S A Chen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

7.  Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells.

Authors:  X Z Sun; D Zhou; S Chen
Journal:  J Steroid Biochem Mol Biol       Date:  1997 Sep-Oct       Impact factor: 4.292

8.  Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.

Authors:  Ikuko Kijima; Toru Itoh; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2005-11-02       Impact factor: 4.292

9.  In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione.

Authors:  M J Reed; A M Owen; L C Lai; N G Coldham; M W Ghilchik; N A Shaikh; V H James
Journal:  Int J Cancer       Date:  1989-08-15       Impact factor: 7.396

10.  Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

Authors:  B Fisher; J P Costantino; C K Redmond; E R Fisher; D L Wickerham; W M Cronin
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

View more
  3 in total

1.  AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor.

Authors:  Shiuan Chen; Dujin Zhou; Li-Yu Hsin; Noriko Kanaya; Cynthie Wong; Richard Yip; Srilatha Sakamuru; Menghang Xia; Yate-Ching Yuan; Kristine Witt; Christina Teng
Journal:  Toxicol Sci       Date:  2014-02-04       Impact factor: 4.849

2.  Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells.

Authors:  Yuanzhong Wang; Yen-Dun Tony Tzeng; Gregory Chang; Xiaoqiang Wang; Shiuan Chen
Journal:  Endocr Relat Cancer       Date:  2020-12       Impact factor: 5.678

3.  Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA.

Authors:  PengMing Sun; XiaoDan Mao; Min Gao; MeiMei Huang; LiLi Chen; GuanYu Ruan; WeiYi Huang; Elena Ioana Braicu; Jalid Sehouli
Journal:  Cancer Manag Res       Date:  2018-08-10       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.